Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Revenue

Blueprint Medicines had revenue of $282.21M in the twelve months ending March 31, 2024, with 37.94% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $96.12M with 51.87% year-over-year growth. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.

• Revenue (ttm): $282.21M
• Revenue Growth: +37.94%
• P/S Ratio: 23.60
• Revenue / Employee: $430,853
• Employees: 655
• Market Cap: 6.79B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	249.38M	45.34M	22.22%
Dec 31, 2022	204.04M	23.96M	13.30%
Dec 31, 2021	180.08M	-613.66M	-77.31%
Dec 31, 2020	793.74M	727.22M	1,093.37%
Dec 31, 2019	66.51M	21.99M	49.39%
Dec 31, 2018	44.52M	23.10M	107.79%
Dec 31, 2017	21.43M	-6.35M	-22.85%
Dec 31, 2016	27.77M	16.37M	143.61%
Dec 31, 2015	11.40M	-	-
Dec 31, 2014	0	-	-
Dec 31, 2013	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.